UNSPSC 51412014: Linsidomine hydrochloride

This classification denotes a vasodilating agent and nitric oxide-releasing compound with the molecular formula C6H10N4O2.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y0054U597M. European Medicines Agency schedules linsidomine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21667. The term linsidomine hydrochloride is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule linsidomine hydrochloride under HS 29349990 and SITC 51579.

As of Q4 2014, LINSIDOMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: C1C(ON[N+]1N2CCOCC2)N.[CL-].

UNSPSC 51412014 Linsidomine hydrochloride is a Commodity code under which state and local governments procure advanced life support medications and generic pharmaceuticals for emergency medical services, healthcare facilities, and state pharmacy benefit programs. The scope of work encompasses supply of specific pharmaceutical products with detailed specifications including National Drug Codes, packaging configurations, dosage forms, and expiration-date requirements; vendors typically furnish products through authorized wholesalers or direct distribution channels and must maintain compliance with cGMP, the Drug Supply Chain Security Act, FDA requirements, and OSHA safety documentation standards. Issuing bodies include city fire departments (emergency medical services), state health and human services commissions, and multistate cooperative purchasing alliances that aggregate demand across state and local government members. The City of Tampa's fire rescue operations and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) are active recent buyers under this code.

Geographic activity concentrates in Florida and Minnesota, with interstate reach through cooperative purchasing vehicles serving Oregon and other MMCAP member jurisdictions. The City of Tampa issued IFB 26P00188 on April 24, 2026, soliciting four line items of advanced life support medications (labetalol, epinephrine, adenosine, and diltiazem) with a response deadline of April 8, 2026 and estimated contract value of $40,000.00; the solicitation included a 5 percent bid discount for Small Local Business Enterprise participation and required Safety Data Sheets and accessibility conformance documentation. MMCAP issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline, requiring vendor pricing submissions through the ePro system and distribution via AmerisourceBergen, Cardinal Health, or Morris & Dickson with contract effectiveness targeted for July 1, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 in late March 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, signaling exploratory procurement activity that may precede formal RFP issuance.